新型肾性贫血药物罗沙司他的研究进展

Abstract
Figure/Table
References (42)
Related Citation (15)

Download: PDF (811 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract

Anemia is a common complication of chronic kidney disease, which seriously affects the life span and quality of life of patients. Roxadustat, which is a oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitors,is first used in the treatment of renal anemia. It promotes the expression of erythropoietin and its receptors, inhibits hypoxia-inducible factor's ubiquitin degradation, maintains hypoxia-inducible factor's stability, improves iron absorption,utilization and transportation, comprehensively controls erythropoiesis. Its effect is distinct and it has become a new way to treat renal anemia. Recently, more and more evidences show that Roxadustat has more new applications. Among them, the mechanism of hypoxia protection has attracted much attention. Related animal studies have confirmed that Roxadustat can exert protective effect on kidney, lung, heart, muscle and bone tissues through anti-oxidative stress and anti-fibrosis. Meanwhile, related clinical trials have documented that roxadustat can effectively correct renal anemia in dialysis and non-dialysis patients, and is not affected by the inflammatory state. It is suitable for all age groups. So,this article reviews the progress of animal and clinical research in roxadustat at home and abroad, in order to provide a new basis for its application.

Key words： Roxadustat Renal anemia Chronic kidney disease Hypoxia-inducible factor Animal study Clinical trial

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Qianqian
	WANG Jiangang
	LIU Xinyu

Cite this article:

LI Qianqian,WANG Jiangang,LIU Xinyu. Research progress of a new renal anemia drug Roxadustat[J]. 中国当代医药, 2022, 29(18): 36-39转43.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I18/36

[1]	谷卉，杜晓刚.维持性血液透析尿毒症患者的预后及其危险因素研究进展[J].中国全科医学，2018，21（18）：2252-2257.
[2]	中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识（2018 修订版）[J].中华肾脏病杂志，2018，34（11）：860-866.
[3]	Wang Y，Wei RB，Su TY，et al.Clinical and pathological factors of renal anaemia in patients with IgA nephropathy in Chinese adults：a cross-sectional study[J].BMJ Open，2019，9（1）：e023479.
[4]	Semenza GL，Wang GL.A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation[J].Mol Cell Biol，1992，12（12）：5447-5454.
[5]	Wang GL，Semenza GL.General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia[J].Proc Natl Acad Sci USA，1993，90（9）：4304-4308.
[6]	彭长坤，刘萍.罗沙司他治疗肾性贫血的作用机制及临床研究进展[J].世界最新医学信息文摘，2019，19（52）：89-91.
[7]	贺晓瑛，潘兴泉，李家国，等.治疗肾性贫血新药——roxadustat[J].临床药物治疗杂志，2018，16（8）：1-3，8.
[8]	蔡蓉，程金科.生物体的氧感受与适应[J].科学，2020，72（1）：10-12，4.
[9]	张晓良，仰欣，涂岩.低氧信号机制的发现与肾性贫血药物治疗进展[J].药学进展，2019，43（12）：914-921.
[10]	刘振宁，张顺，高嵩岚，等.Nrf2 在百草枯中毒致大鼠急性肺损伤中的表达和意义[J].中国现代医学杂志，2015，25（2）：1-6.
[11]	秦瑞怡，边立功，钟莲梅，等.天麻素调控Nrf2 信号通路在癫痫中的抗炎作用[J].神经解剖学杂志，2018，34（2）：147-152.
[12]	Li X，Zou Y，Xing J，et al.Pretreatment with Roxadustat（FG-4592） Attenuates Folic Acid-Induced Kidney Injury through Antiferroptosis via Akt/GSK-3β/Nrf2 Pathway[J].Oxid Med Cell Longev，2020，2020：6286984.
[13]	Del Balzo U，Signore PE，Walkinshaw G，et al.Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat，a Novel Treatment of Anemia of Chronic Kidney Disease[J].J Pharmacol Exp Ther，2020，374（2）：342-353.
[14]	Yang Y，Yu X，Zhang Y，et al.Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat （FG-4592） protects against cisplatin-induced acute kidney injury[J].Clin Sci （Lond），2018，132（7）：825-838.
[18]	Huang H，Wang X，Zhang X，et al.Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo[J].Toxicol Lett，2020，331：112-121.
[22]	张馨文，刘雯玥，肖桂芝，等.低氧诱导因子脯氨酰羟化酶抑制剂roxadustat[J].现代药物与临床，2016，31（4）：551-556.
[30]	佚名.全球首创肾性贫血新药罗沙司他在中国率先获批[J].石河子科技，2019（1）：49.
[31]	涂岩，张晓良.低氧诱导因子脯氨酰羟化酶抑制剂罗沙司他临床应用若干问题[J].临床肾脏病杂志，2020，20（7）：594-597.
[15]	Miao AF，Liang JX，Yao L，et al.Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat （FG-4592） protects against renal ischemia/reperfusion injury by inhibiting inflammation[J].Ren Fail，2021，43（1）：803-810.
[16]	Han F，Wu G，Han S，et al.Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat （FG-4592） alleviates sepsis-induced acute lung injury[J].Respir Physiol Neurobiol，2020，281：103506.
[17]	Huang LT，Chou HC，Chen CM.Roxadustat attenuates hyperoxia-induced lung injury by upregulating proangiogenic factors in newborn mice[J].Pediatr Neonatol，2021，62（4）：369-378.
[19]	Long G，Chen H，Wu M，et al.Antianemia Drug Roxadustat（FG-4592） Protects Against Doxorubicin-Induced Cardiotoxicity by Targeting Antiapoptotic and Antioxidative Pathways[J].Front Pharmacol，2020，11：1191.
[20]	Zhu Y，Wang Y，Jia Y，et al.Roxadustat promotes angiogenesis through HIF-1α/VEGF/VEGFR2 signaling and accelerates cutaneous wound healing in diabetic rats[J].Wound Repair Regen，2019，27（4）：324-334.
[21]	Chen C，Yan S，Qiu S，et al.HIF/Ca2+/NO/ROS is critical in roxadustat treating bone fracture by stimulating the proliferation and migration of BMSCs[J].Life Sci，2021，264：118684.
[23]	Groenendaal-van de Meent D，Adel MD，Noukens J，et al.Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat，an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor[J].Clin Drug Investig，2016，36（9）：743-751.
[24]	Groenendaal-van de Meent D，den Adel M，Rijnders S，et al.The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat （FG-4592） and Warfarin in Healthy Volunteers：A Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction Study[J].Clin Ther，2016，38（4）：918-928.
[25]	Besarab A，Provenzano R，Hertel J，et al.Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat （FG-4592） to treat anemia in nondialysisdependent chronic kidney disease （NDD-CKD）patients[J].Nephrol Dial Transplant，2015，30（10）：1665-1673.
[26]	Provenzano R，Besarab A，Sun CH，et al.Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat（FG-4592） for the Treatment of Anemia in Patients with CKD[J].Clin J Am Soc Nephrol，2016，11（6）：982-991.
[27]	Besarab A，Chernyavskaya E，Motylev I，et al.Roxadustat（FG-4592）：Correction of Anemia in Incident Dialysis Patients[J].J Am Soc Nephrol，2016，27（4）：1225-1233.
[32]	珐博进（中国）医药技术开发有限公司.罗沙司他胶囊说明书（中国）[EB/OL].（2018-12-17）[2021-12-06].
[33]	FibroGen Inc.罗沙司他胶囊说明书（日本）[EB/OL].（2019-11-01）[2021-12-06].
[34]	李宏彬，梁军，马强.罗沙司他胶囊与重组人促红素治疗肾性贫血的效果及预后比较[J].中国医药导报，2020，17（8）：178-181.
[35]	孙艳玲，谢华，康喆，等.罗沙司他治疗初始血液透析患者肾性贫血20 例疗效研究[J].中国实用内科杂志，2020，40（11）：942-946.
[28]	Chen N，Hao C，Liu BC，et al.Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis[J].N Engl J Med，2019，381（11）：1011-1022.
[29]	Chen N，Hao C，Peng X，et al.Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis[J].N Engl J Med，2019，381（11）：1001-1010.
[36]	朱新旺，张丛笑，徐天华，等.罗沙司他治疗腹膜透析肾性贫血29 例疗效分析[J].中国实用内科杂志，2020，40（11）：932-936.
[37]	甘良英.罗沙司他治疗血液透析患者重症感染后贫血1 例报告[J].中国实用内科杂志，2020，40（11）：952-954.
[38]	田秀丽，田秀芳，李芳.罗沙司他治疗儿童肾性贫血的疗效观察[J].中国妇幼保健，2020，35（18）：3415-3417.
[39]	Hou YP，Mao XY，Wang C，et al.Roxadustat treatment for anemia in peritoneal dialysis patients：A randomized controlled trial[J].J Formos Med Assoc，2022，121（2）：529-538.
[40]	Akizawa T，Iwasaki M，Otsuka T，et al.Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD[J].Kidney Int Rep，2021，6（7）：1810-1828.
[41]	Ichii M，Mori K，Miyaoka D，et al.Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis[J].BMC Nephrol，2021，22（1）：104.
[42]	Yang Q，Wang X.A case report of rhabdomyolysis caused by the use of roxadustat in the treatment caused by renal anaemia[J].Int J Clin Pract，2021，75（6）：e14011.